Veracyte, Inc(NASDAQ:VCYT) 
Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in orde...
Website: http://www.veracyte.com
Founded: 2006
Full Time Employees: 354
Sector: Healthcare
Industry: Biotechnology
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||
testing revenue | 135,091,000 | 135,826,000 | 127,756,000 | 122,263,000 | 107,309,000 | 112,152,000 | 109,536,000 | 106,970,000 | 90,303,000 | 90,385,000 | 82,012,000 | 81,749,000 | 72,396,000 | 70,269,000 | 64,577,000 | 59,718,000 | 55,980,000 | 53,414,000 | 50,897,000 | 50,793,000 | 33,078,000 | 31,497,000 | 28,270,000 | 15,212,000 | 26,991,000 | |||||||||||||||||||||||
product revenue | 3,679,000 | 3,848,000 | 3,301,000 | 3,598,000 | 3,580,000 | 3,019,000 | 3,188,000 | 3,906,000 | 3,537,000 | 3,665,000 | 4,020,000 | 4,011,000 | 3,892,000 | 3,231,000 | 3,314,000 | 3,108,000 | 2,979,000 | 2,758,000 | 2,959,000 | 2,688,000 | 3,059,000 | 2,696,000 | 2,027,000 | 1,713,000 | 3,409,000 | |||||||||||||||||||||||
biopharmaceutical and other revenue | 301,000 | 962,000 | 815,000 | 4,303,000 | 3,584,000 | 3,461,000 | 3,136,000 | 3,552,000 | 3,004,000 | 4,149,000 | 4,076,000 | 4,562,000 | 6,134,000 | 6,797,000 | 7,701,000 | 10,038,000 | 8,824,000 | 11,164,000 | 6,514,000 | |||||||||||||||||||||||||||||
total revenue | 139,071,000 | 140,636,000 | 131,872,000 | 130,164,000 | 114,473,000 | 118,632,000 | 115,860,000 | 114,428,000 | 96,844,000 | 98,199,000 | 90,108,000 | 90,322,000 | 82,422,000 | 80,297,000 | 75,592,000 | 72,864,000 | 67,783,000 | 67,336,000 | 60,370,000 | 55,105,000 | 36,703,000 | 34,536,000 | 31,121,000 | 20,704,000 | 31,122,000 | |||||||||||||||||||||||
yoy | 21.49% | 18.55% | 13.82% | 13.75% | 18.20% | 20.81% | 28.58% | 26.69% | 17.50% | 22.29% | 19.20% | 23.96% | 21.60% | 19.25% | 25.21% | 32.23% | 84.68% | 94.97% | 93.98% | 166.16% | 17.93% | |||||||||||||||||||||||||||
qoq | -1.11% | 6.65% | 1.31% | 13.71% | -3.51% | 2.39% | 1.25% | 18.16% | -1.38% | 8.98% | -0.24% | 9.58% | 2.65% | 6.22% | 3.74% | 7.50% | 0.66% | 11.54% | 9.55% | 50.14% | 6.27% | 10.97% | 50.31% | -33.47% | ||||||||||||||||||||||||
cost of revenue: | ||||||||||||||||||||||||||||||||||||||||||||||||
cost of testing revenue | 33,306,000 | 33,118,000 | 33,777,000 | 32,407,000 | 28,260,000 | 31,645,000 | 29,029,000 | 27,920,000 | 25,979,000 | 24,105,000 | 21,827,000 | 23,333,000 | 19,648,000 | 19,394,000 | 19,816,000 | 18,584,000 | 17,523,000 | 16,366,000 | 16,073,000 | 15,589,000 | 10,832,000 | 9,756,000 | 9,118,000 | 6,471,000 | 10,568,000 | |||||||||||||||||||||||
cost of product revenue | 1,891,000 | 2,621,000 | 3,015,000 | 1,749,000 | 1,422,000 | 2,800,000 | 1,792,000 | 1,874,000 | 2,644,000 | 1,753,000 | 2,436,000 | 2,315,000 | 2,162,000 | 2,618,000 | 1,981,000 | 1,646,000 | 1,575,000 | 1,583,000 | 1,491,000 | 1,323,000 | 1,490,000 | 1,382,000 | 1,048,000 | 932,000 | 1,559,000 | |||||||||||||||||||||||
cost of biopharmaceutical and other revenue | 8,000 | 217,000 | 1,091,000 | 3,572,000 | 2,698,000 | 2,622,000 | 3,112,000 | 3,812,000 | 2,838,000 | 3,518,000 | 3,347,000 | 4,040,000 | 4,419,000 | 4,819,000 | 4,211,000 | 4,800,000 | 4,615,000 | 4,933,000 | 4,079,000 | |||||||||||||||||||||||||||||
intangible asset amortization - cost of revenue | 2,707,000 | 2,707,000 | 2,707,000 | 2,667,000 | 2,585,000 | 2,811,000 | 2,917,000 | 2,909,000 | ||||||||||||||||||||||||||||||||||||||||
total cost of revenue | 37,912,000 | 38,663,000 | 40,590,000 | 40,395,000 | 34,965,000 | 39,878,000 | 36,850,000 | 36,515,000 | ||||||||||||||||||||||||||||||||||||||||
gross profit | 101,159,000 | 101,973,000 | 91,282,000 | 89,769,000 | 79,508,000 | 78,754,000 | 79,010,000 | 77,913,000 | ||||||||||||||||||||||||||||||||||||||||
yoy | 27.23% | 29.48% | 15.53% | 15.22% | ||||||||||||||||||||||||||||||||||||||||||||
qoq | -0.80% | 11.71% | 1.69% | 12.91% | 0.96% | -0.32% | 1.41% | |||||||||||||||||||||||||||||||||||||||||
gross margin % | 72.74% | 72.51% | 69.22% | 68.97% | 69.46% | 66.39% | 68.19% | 68.09% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% |
operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||||||
research and development | 27,098,000 | 20,849,000 | 15,981,000 | 16,264,000 | 17,720,000 | 19,290,000 | 17,574,000 | 16,465,000 | 15,965,000 | 18,673,000 | 13,322,000 | 12,541,000 | 12,769,000 | 11,287,000 | 10,773,000 | 9,377,000 | 9,166,000 | 10,252,000 | 8,006,000 | 6,249,000 | 5,336,000 | 4,586,000 | 4,042,000 | 4,169,000 | 4,407,000 | 4,443,000 | 3,643,000 | 3,330,000 | 3,435,000 | 3,125,000 | 3,419,000 | 4,601,000 | 3,675,000 | 3,202,000 | 3,046,000 | 3,603,000 | 4,030,000 | 3,590,000 | 4,006,000 | 4,267,000 | 3,461,000 | 3,563,000 | 3,103,000 | 2,787,000 | 2,233,000 | 2,243,000 | 2,126,000 | 2,028,000 |
selling and marketing | 27,156,000 | 25,940,000 | 24,455,000 | 25,316,000 | 24,454,000 | 24,824,000 | 22,612,000 | 24,216,000 | 23,782,000 | 25,260,000 | 24,344,000 | 25,756,000 | 26,130,000 | 24,127,000 | 25,678,000 | 24,001,000 | 23,754,000 | 22,212,000 | 21,670,000 | 19,662,000 | 16,296,000 | 13,149,000 | 10,955,000 | 10,701,000 | 17,584,000 | 14,183,000 | 13,088,000 | 13,943,000 | 12,477,000 | 10,066,000 | 10,081,000 | 9,623,000 | 11,543,000 | 9,045,000 | 7,885,000 | 7,994,000 | 7,336,000 | 5,832,000 | 7,087,000 | 8,263,000 | 7,066,000 | 6,048,000 | 6,937,000 | 5,620,000 | 5,533,000 | 5,101,000 | 4,336,000 | 3,291,000 |
general and administrative | 23,680,000 | 17,367,000 | 27,278,000 | 32,331,000 | 33,808,000 | 26,913,000 | 25,742,000 | 31,745,000 | 26,210,000 | 23,795,000 | 16,334,000 | 25,047,000 | 22,463,000 | 18,208,000 | 17,600,000 | 19,798,000 | 20,912,000 | 18,849,000 | 20,749,000 | 15,473,000 | 46,282,000 | 12,413,000 | 8,546,000 | 7,957,000 | 7,813,000 | 8,581,000 | 6,624,000 | 6,920,000 | 6,904,000 | 6,645,000 | 5,742,000 | 5,932,000 | 5,644,000 | 5,357,000 | 5,520,000 | 6,192,000 | 6,019,000 | 5,725,000 | 5,763,000 | 6,071,000 | 6,228,000 | 5,728,000 | 5,536,000 | 5,798,000 | 5,715,000 | 3,928,000 | 3,982,000 | 3,244,000 |
intangible asset amortization - operating expenses | 579,000 | 622,000 | 622,000 | 621,000 | 622,000 | 798,000 | 880,000 | 881,000 | ||||||||||||||||||||||||||||||||||||||||
total operating expenses | 78,513,000 | 64,778,000 | 68,336,000 | 95,037,000 | 76,604,000 | 74,579,000 | 66,993,000 | 73,307,000 | 101,500,000 | 133,706,000 | 121,847,000 | 98,373,000 | 92,920,000 | 85,717,000 | 85,272,000 | 83,597,000 | 83,031,000 | 79,669,000 | 77,051,000 | 62,579,000 | 82,118,000 | 42,608,000 | 35,187,000 | 31,755,000 | 43,322,000 | 37,927,000 | 32,736,000 | 33,236,000 | 31,596,000 | 28,807,000 | 27,770,000 | 28,668,000 | 28,996,000 | 25,640,000 | 23,887,000 | 25,015,000 | 23,949,000 | 21,929,000 | 23,489,000 | 25,169,000 | 23,301,000 | 21,223,000 | 20,982,000 | 18,771,000 | 17,649,000 | 15,238,000 | 14,051,000 | 11,695,000 |
income from operations | 22,646,000 | 37,195,000 | 22,946,000 | -5,268,000 | 2,904,000 | 4,175,000 | 12,017,000 | 4,606,000 | -4,656,000 | -35,507,000 | -31,739,000 | -8,051,000 | -10,498,000 | -5,420,000 | -9,680,000 | -10,733,000 | -15,248,000 | -12,333,000 | -16,681,000 | -7,474,000 | -45,415,000 | -8,072,000 | -4,066,000 | -11,051,000 | -12,200,000 | -8,197,000 | -1,763,000 | -3,100,000 | -2,067,000 | -3,057,000 | -4,304,000 | -5,917,000 | -8,955,000 | -6,044,000 | -6,368,000 | -6,609,000 | -7,517,000 | -3,672,000 | -4,886,000 | -10,494,000 | ||||||||
yoy | 679.82% | 790.90% | 90.95% | -214.37% | -162.37% | -111.76% | -137.86% | -157.21% | -55.65% | 555.11% | 227.88% | -24.99% | -31.15% | -56.05% | -41.97% | 43.60% | -66.43% | 52.79% | 310.26% | -32.37% | 272.25% | -1.52% | 130.63% | 256.48% | 490.23% | 168.14% | -59.04% | -47.61% | -76.92% | -49.42% | -32.41% | -10.47% | 19.13% | 64.60% | 30.33% | -37.02% | ||||||||||||
qoq | -39.12% | 62.10% | -535.57% | -281.40% | -30.44% | -65.26% | 160.90% | -198.93% | -86.89% | 11.87% | 294.22% | -23.31% | 93.69% | -44.01% | -9.81% | -29.61% | 23.64% | -26.07% | 123.19% | -83.54% | 462.62% | 98.52% | -63.21% | -9.42% | 48.83% | 364.95% | -43.13% | 49.98% | -32.38% | -28.97% | -27.26% | -33.93% | 48.16% | -5.09% | -3.65% | -12.08% | 104.71% | -24.85% | -53.44% | |||||||||
operating margin % | 16.28% | 26.45% | 17.40% | -4.05% | 2.54% | 3.52% | 10.37% | 4.03% | -4.81% | -36.16% | -35.22% | -8.91% | -12.74% | -6.75% | -12.81% | -14.73% | -22.50% | -18.32% | -27.63% | -13.56% | -123.74% | -23.37% | -13.07% | -53.38% | -39.20% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | -Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% |
other income | 7,328,000 | 3,439,000 | -4,057,000 | 6,518,000 | 4,524,000 | -732,000 | 4,831,000 | 2,755,000 | 2,748,000 | 5,035,000 | 1,967,000 | -226,000 | 2,407,000 | 1,979,000 | 805,000 | 1,086,000 | 784,000 | 1,016,000 | 1,202,000 | -1,653,000 | -195,000 | 82,000 | -3,000 | 91,000 | 539,000 | 820,000 | 1,091,000 | 841,000 | 453,000 | 488,000 | 333,000 | 150,000 | 226,000 | 123,000 | 134,000 | 119,000 | 100,000 | 75,000 | 48,000 | 36,000 | 43,000 | 35,000 | 28,000 | 32,000 | 23,000 | 19,000 | 12,000 | |
income before income taxes | 29,974,000 | 40,634,000 | 18,889,000 | 1,250,000 | 7,428,000 | 3,443,000 | 16,848,000 | 7,361,000 | -1,908,000 | -11,535,000 | -29,772,000 | -8,277,000 | -8,091,000 | -8,246,500 | -8,875,000 | -9,647,000 | -14,464,000 | |||||||||||||||||||||||||||||||
income tax provision | 1,267,000 | -515,000 | -248,000 | 2,230,000 | 381,000 | -1,670,000 | 1,693,000 | 1,627,000 | ||||||||||||||||||||||||||||||||||||||||
net income | 28,707,000 | 41,149,000 | 19,137,000 | -980,000 | 7,047,000 | 5,113,000 | 15,155,000 | 5,734,000 | -1,864,000 | -28,293,000 | -29,618,000 | -8,402,000 | -8,091,000 | -3,844,000 | -8,723,000 | -9,532,000 | -14,461,000 | -10,528,000 | -14,129,000 | |||||||||||||||||||||||||||||
yoy | 307.36% | 704.79% | 26.28% | -117.09% | -478.06% | -118.07% | -151.17% | -168.25% | -76.96% | 636.03% | 239.54% | -11.85% | -44.05% | -63.49% | -38.26% | |||||||||||||||||||||||||||||||||
qoq | -30.24% | 115.02% | -2052.76% | -113.91% | 37.83% | -66.26% | 164.30% | -407.62% | -93.41% | -4.47% | 252.51% | 3.84% | 110.48% | -55.93% | -8.49% | -34.08% | 37.36% | -25.49% | ||||||||||||||||||||||||||||||
net income margin % | 20.64% | 29.26% | 14.51% | -0.75% | 6.16% | 4.31% | 13.08% | 5.01% | -1.92% | -28.81% | -32.87% | -9.30% | -9.82% | -4.79% | -11.54% | -13.08% | -21.33% | -15.64% | -23.40% | 0% | 0% | 0% | 0% | 0% | 0% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% |
earnings per share: | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 0.36 | 0.52 | 0.24 | -0.01 | 0.09 | 0.07 | 0.2 | 0.07 | ||||||||||||||||||||||||||||||||||||||||
diluted | 0.35 | 0.5 | 0.24 | -0.01 | 0.09 | 0.06 | 0.19 | 0.07 | ||||||||||||||||||||||||||||||||||||||||
shares used to compute earnings per common share: | ||||||||||||||||||||||||||||||||||||||||||||||||
basic | 79,536,601 | 200,107 | 78,725,139 | 78,391,502 | 78,028,254 | 377,457 | 77,013,831 | 76,538,325 | ||||||||||||||||||||||||||||||||||||||||
diluted | 81,313,588 | 626,754 | 79,691,703 | 78,391,502 | 80,056,024 | 823,320 | 78,464,654 | 77,163,149 | ||||||||||||||||||||||||||||||||||||||||
impairment of assets | 20,505,000 | |||||||||||||||||||||||||||||||||||||||||||||||
impairment of long-lived assets | 2,754,000 | 185,000 | 429,000 | 32,039,000 | 34,900,000 | |||||||||||||||||||||||||||||||||||||||||||
intangible asset amortization | 3,653,000 | 4,563,000 | 5,337,000 | 5,341,000 | 5,329,000 | 5,264,000 | 5,213,000 | 5,391,000 | 5,486,000 | 5,474,000 | 4,983,000 | 3,723,000 | 1,801,000 | 1,273,000 | 1,274,000 | 1,273,000 | 1,275,000 | 601,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | 267,000 | 266,000 | 267,000 | |||||||||||||
income tax benefit | -44,000 | -7,250 | -154,000 | -67,500 | -152,000 | -115,000 | -3,000 | -789,000 | -1,350,000 | -152,000 | -3,795,000 | |||||||||||||||||||||||||||||||||||||
net loss per common share, basic and diluted | -20 | -380 | -410 | -120 | -110 | -50 | -120 | -130 | -200 | -140 | -200 | -130 | -660 | -140 | -80 | -220 | -240 | -160 | -20 | -50 | -50 | -60 | -120 | -180 | -270 | -240 | -210 | -220 | -240 | -120 | -200 | -400 | -360 | -320 | -350 | -340 | -370 | -310 | -320 | -6,590 | ||||||||
shares used to compute net loss per common share, basic and diluted | 74,759,789,000 | 155,886,000 | 72,804,770,000 | 72,478,662,000 | 72,175,457,000 | 93,196,000 | 71,656,694,000 | 71,476,966,000 | 71,229,672,000 | 1,069,674,000 | 69,743,733,000 | 67,316,065,000 | 63,331,702,000 | 1,606,481,000 | 54,858,052,000 | 50,212,123,000 | 49,792,631,000 | 996,675,000 | 48,588,296,000 | 45,586,081,000 | 41,168,593,000 | 1,250,623,000 | 38,620,036,000 | 34,314,234,000 | 34,271,254,000 | 43,912,000 | 33,946,748,000 | 33,873,128,000 | 33,823,889,000 | 965,372,000 | 27,916,819,000 | 27,859,918,000 | 27,817,993,000 | 27,640,806,000 | 26,048,934,000 | 22,539,723,000 | 21,648,660,000 | 21,237,196,000 | 21,148,342,000 | 955,890,000 | ||||||||
income tax expense | 125,000 | |||||||||||||||||||||||||||||||||||||||||||||||
loss before income tax benefit | -11,317,000 | -15,479,000 | -9,190,000 | -45,663,000 | ||||||||||||||||||||||||||||||||||||||||||||
biopharmaceutical revenue | 1,624,000 | 566,000 | 343,000 | 824,000 | 3,779,000 | 722,000 | ||||||||||||||||||||||||||||||||||||||||||
cost of biopharmaceutical revenue | 560,000 | 81,000 | 49,000 | 204,000 | 252,000 | 116,000 | ||||||||||||||||||||||||||||||||||||||||||
interest expense | -63,000 | -53,000 | -54,000 | -55,000 | -65,000 | -55,000 | -81,000 | -58,000 | -235,000 | -303,000 | -536,000 | -498,000 | -481,000 | -448,000 | -2,518,000 | -815,000 | -808,000 | -800,000 | -806,000 | -799,000 | -785,000 | |||||||||||||||||||||||||||
net loss and comprehensive loss | -9,038,000 | -41,868,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | -7,458,000 | -730,000 | -2,494,000 | -1,917,000 | -3,105,000 | -4,469,000 | -6,248,000 | -9,177,000 | -8,439,000 | -7,049,000 | -7,298,000 | -8,217,000 | -4,403,000 | -5,637,000 | -11,243,000 | -10,075,000 | -8,945,000 | -9,136,000 | -7,610,000 | -7,902,000 | -6,655,000 | -6,674,000 | -6,303,000 | |||||||||||||||||||
collaboration revenue | ||||||||||||||||||||||||||||||||||||||||||||||||
revenue | 22,659,500 | 30,973,000 | 30,136,000 | 29,529,000 | 25,750,000 | 23,466,000 | 22,751,000 | 20,041,000 | 19,596,000 | 17,519,000 | 18,406,000 | 16,432,000 | 18,257,000 | 18,603,000 | 14,675,000 | 13,550,000 | 12,335,000 | 11,908,000 | 11,218,000 | 9,838,000 | 8,677,000 | 7,476,000 | 5,594,000 | |||||||||||||||||||||||||
cost of revenue | 6,601,000 | 9,114,000 | 8,777,000 | 8,513,000 | 8,704,000 | 8,261,000 | 8,246,000 | 7,867,000 | 7,769,000 | 7,169,000 | 6,960,000 | 6,297,000 | 6,515,000 | 6,367,000 | 6,301,000 | 6,279,000 | 5,618,000 | 5,139,000 | 4,566,000 | 4,168,000 | 3,966,000 | 3,607,000 | 3,132,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 263,136,000 | 362,578,000 | 315,573,000 | 219,499,000 | 186,120,000 | 239,087,000 | 274,079,000 | 235,915,000 | 209,188,000 | 216,454,000 | 202,463,000 | 191,142,000 | 177,890,000 | 154,247,000 | 170,112,000 | 153,447,000 | 163,615,000 | 173,197,000 | 164,029,000 | 327,545,000 | 324,062,000 | 349,364,000 | 345,080,000 | 147,450,000 | 153,132,000 | 159,317,000 | 195,662,000 | 192,647,000 | 67,841,000 | 77,995,000 | 77,846,000 | 23,758,000 | 27,152,000 | 33,891,000 | 41,195,000 | 46,463,000 | 51,506,000 | 59,219,000 | 31,699,000 | 38,993,000 | 47,456,000 | 46,116,000 | 51,045,000 | 25,798,000 | 44,002,000 | 57,998,000 | 64,237,000 | 15,426,000 |
short-term investments | 175,924,000 | 50,311,000 | 50,855,000 | 101,220,000 | 101,235,000 | 50,354,000 | 24,605,000 | 10,551,000 | ||||||||||||||||||||||||||||||||||||||||
accounts receivable | 50,112,000 | 44,660,000 | 47,826,000 | 50,814,000 | 53,781,000 | 46,525,000 | 48,807,000 | 50,304,000 | 46,665,000 | 40,378,000 | 39,297,000 | 42,365,000 | 45,489,000 | 44,021,000 | 40,068,000 | 40,448,000 | 42,481,000 | 41,461,000 | 40,309,000 | 31,864,000 | 27,877,000 | 18,461,000 | 17,629,000 | 15,306,000 | 19,091,000 | 19,329,000 | 23,613,000 | 19,626,000 | 16,615,000 | 13,168,000 | 12,262,000 | 13,006,000 | 13,198,000 | 12,716,000 | 11,635,000 | 11,027,000 | 9,125,000 | 8,756,000 | 6,312,000 | 3,387,000 | 3,230,000 | 3,520,000 | 3,586,000 | 2,564,000 | 1,180,000 | 1,430,000 | 1,191,000 | 714,000 |
supplies | 21,416,000 | 11,225,000 | 9,824,000 | 6,674,000 | 6,308,000 | 4,657,000 | 4,456,000 | 7,041,000 | 6,094,000 | 6,806,000 | 6,608,000 | 5,104,000 | 3,768,000 | 3,402,000 | 3,463,000 | |||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 11,587,000 | 10,281,000 | 14,643,000 | 18,128,000 | 17,762,000 | 14,551,000 | 13,604,000 | 15,629,000 | 16,237,000 | 12,661,000 | 13,516,000 | 14,401,000 | 14,818,000 | 11,469,000 | 14,538,000 | 15,999,000 | 20,015,000 | 17,219,000 | 15,146,000 | 5,263,000 | 3,845,000 | 3,197,000 | 3,150,000 | 2,891,000 | 3,045,000 | 2,235,000 | 2,196,000 | 2,573,000 | 2,392,000 | 2,387,000 | 1,803,000 | 1,822,000 | 2,142,000 | 1,997,000 | 1,617,000 | 1,933,000 | 2,101,000 | 2,057,000 | 1,405,000 | 1,395,000 | 1,618,000 | 3,371,000 | 1,735,000 | 1,179,000 | 1,711,000 | 1,450,000 | 1,014,000 | 2,938,000 |
total current assets | 522,175,000 | 488,376,000 | 449,224,000 | 414,681,000 | 383,152,000 | 372,267,000 | 356,854,000 | 321,106,000 | 290,418,000 | 285,621,000 | 271,163,000 | 259,480,000 | 251,503,000 | 248,636,000 | 238,516,000 | 235,045,000 | 238,483,000 | 243,102,000 | 229,308,000 | 371,346,000 | 362,092,000 | 375,679,000 | 370,315,000 | 172,688,000 | 181,362,000 | 187,687,000 | 228,079,000 | 219,950,000 | 90,616,000 | 96,952,000 | 95,374,000 | 41,635,000 | 47,049,000 | 53,928,000 | 58,207,000 | 62,860,000 | 66,295,000 | 73,627,000 | 42,952,000 | 47,397,000 | 56,194,000 | 57,331,000 | 60,714,000 | 33,691,000 | 50,668,000 | 64,178,000 | 69,163,000 | 20,470,000 |
property, plant and equipment | 22,652,000 | 22,192,000 | 18,900,000 | 18,552,000 | 22,529,000 | 22,953,000 | 21,194,000 | 22,291,000 | 21,566,000 | 20,584,000 | 19,288,000 | 18,510,000 | 18,072,000 | |||||||||||||||||||||||||||||||||||
right-of-use assets, operating leases | 35,865,000 | 36,599,000 | 37,301,000 | 38,679,000 | 47,624,000 | 48,189,000 | 17,031,000 | 18,116,000 | 11,167,000 | 10,277,000 | 11,297,000 | 12,455,000 | 11,308,000 | 13,885,000 | 14,816,000 | 15,663,000 | ||||||||||||||||||||||||||||||||
intangible assets | 85,863,000 | 89,148,000 | 92,477,000 | 95,806,000 | 99,094,000 | 102,301,000 | 108,873,000 | 112,532,000 | 116,348,000 | 88,593,000 | 123,567,000 | 164,744,000 | 170,226,000 | 174,866,000 | 176,542,000 | 184,367,000 | 196,228,000 | 202,731,000 | 209,521,000 | 155,700,000 | 159,423,000 | |||||||||||||||||||||||||||
goodwill | 767,154,000 | 767,154,000 | 767,154,000 | 773,255,000 | 754,272,000 | 745,800,000 | 762,117,000 | 752,107,000 | 753,853,000 | 702,984,000 | 693,176,000 | 698,920,000 | 699,718,000 | 695,891,000 | 676,885,000 | 690,040,000 | 704,368,000 | 707,904,000 | 714,273,000 | 471,764,000 | 474,838,000 | 2,725,000 | 2,725,000 | 2,725,000 | 2,725,000 | 2,725,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | 1,057,000 | |||
restricted cash | 1,657,000 | 1,648,000 | 1,637,000 | 1,654,000 | 1,645,000 | 1,544,000 | 1,080,000 | 1,088,000 | 1,082,000 | 876,000 | 870,000 | 889,000 | 749,000 | 749,000 | 749,000 | 749,000 | 749,000 | 749,000 | 749,000 | 749,000 | 749,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 603,000 | 120,000 | 120,000 | 120,000 | 120,000 | 120,000 | 238,000 | 118,000 | 118,000 | 118,000 | 100,000 | 118,000 | 118,000 | |||
other assets | 1,034,000 | 902,000 | 1,094,000 | 1,477,000 | 7,095,000 | 6,981,000 | 7,872,000 | 7,087,000 | 5,639,000 | 5,971,000 | 5,582,000 | 6,116,000 | 5,543,000 | 5,418,000 | 2,143,000 | 1,993,000 | 1,799,000 | 2,198,000 | 1,636,000 | 1,504,000 | 2,286,000 | 1,399,000 | 2,303,000 | 1,271,000 | 1,302,000 | 1,437,000 | 1,228,000 | 1,061,000 | 1,049,000 | 1,086,000 | 837,000 | 598,000 | 466,000 | 326,000 | 178,000 | 134,000 | 127,000 | 134,000 | 203,000 | 172,000 | 208,000 | 195,000 | 185,000 | 180,000 | 179,000 | 142,000 | 145,000 | 157,000 |
total assets | 1,436,400,000 | 1,406,019,000 | 1,367,787,000 | 1,344,104,000 | 1,315,411,000 | 1,300,035,000 | 1,275,021,000 | 1,234,327,000 | 1,200,073,000 | 1,114,906,000 | 1,124,943,000 | 1,161,114,000 | 1,157,119,000 | 1,156,422,000 | 1,125,957,000 | 1,144,198,000 | 1,173,589,000 | 1,187,825,000 | 1,186,356,000 | 1,027,435,000 | 1,025,136,000 | 457,163,000 | 454,151,000 | 256,737,000 | 267,100,000 | 275,212,000 | 260,307,000 | 252,377,000 | 123,537,000 | 120,638,000 | 119,077,000 | 65,461,000 | 71,190,000 | 78,669,000 | 83,659,000 | 88,347,000 | 92,606,000 | 101,034,000 | 69,650,000 | 74,832,000 | 84,267,000 | 80,853,000 | 82,503,000 | 55,060,000 | 71,814,000 | 67,750,000 | 72,454,000 | 23,571,000 |
liabilities and stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 6,908,000 | 4,593,000 | 5,509,000 | 11,447,000 | 15,709,000 | 8,634,000 | 9,670,000 | 12,084,000 | 12,152,000 | 12,943,000 | 12,531,000 | 12,895,000 | 15,655,000 | 11,911,000 | 11,114,000 | 10,328,000 | 11,273,000 | 12,360,000 | 11,201,000 | 8,472,000 | 7,137,000 | 3,116,000 | 1,932,000 | 2,224,000 | 7,665,000 | 2,328,000 | 5,568,000 | 4,061,000 | 4,064,000 | 2,516,000 | 1,175,000 | 1,962,000 | 3,356,000 | 3,853,000 | 3,161,000 | 2,349,000 | 2,611,000 | 2,424,000 | 3,081,000 | 2,705,000 | 4,340,000 | 6,644,000 | 2,688,000 | 6,854,000 | 8,587,000 | 8,539,000 | 7,214,000 | 5,604,000 |
accrued liabilities | 43,129,000 | 48,801,000 | 48,373,000 | 43,707,000 | 35,928,000 | 43,826,000 | 43,872,000 | 43,455,000 | 30,293,000 | 38,427,000 | 34,828,000 | 34,427,000 | 30,641,000 | 37,774,000 | 32,137,000 | 33,565,000 | 38,543,000 | 39,475,000 | 29,044,000 | 20,756,000 | 16,254,000 | 11,705,000 | 10,445,000 | 9,386,000 | 10,079,000 | 13,734,000 | 9,760,000 | 9,820,000 | 8,788,000 | 9,186,000 | 9,261,000 | 8,429,000 | 8,483,000 | 8,175,000 | 8,058,000 | 8,450,000 | 6,800,000 | 9,110,000 | 7,189,000 | 8,910,000 | 7,021,000 | 7,365,000 | 7,217,000 | 5,396,000 | 6,106,000 | 5,128,000 | 5,267,000 | 4,416,000 |
current portion of deferred revenue | 749,000 | 1,160,000 | 417,000 | 1,450,000 | 1,712,000 | 1,673,000 | 2,033,000 | 2,195,000 | 2,602,000 | 2,008,000 | 2,214,000 | 2,378,000 | 2,194,000 | 2,613,000 | 3,863,000 | 4,193,000 | 4,878,000 | 4,646,000 | 3,440,000 | 566,000 | 454,000 | 371,000 | ||||||||||||||||||||||||||
current portion of acquisition-related contingent consideration | 982,000 | 1,332,000 | 13,571,000 | 13,415,000 | 14,360,000 | 16,981,000 | 7,391,000 | 7,348,000 | 6,934,000 | 2,657,000 | 2,574,000 | 3,359,000 | 3,300,000 | 6,060,000 | 5,913,000 | 5,998,000 | 2,703,000 | 2,682,000 | 2,646,000 | 3,375,000 | ||||||||||||||||||||||||||||
current portion of operating lease liabilities | 4,347,000 | 4,051,000 | 4,282,000 | 6,414,000 | 7,409,000 | 7,500,000 | 7,294,000 | 7,185,000 | 5,982,000 | 5,105,000 | 5,007,000 | 4,973,000 | 4,076,000 | 4,070,000 | 3,958,000 | 3,930,000 | 3,849,000 | 3,630,000 | ||||||||||||||||||||||||||||||
total current liabilities | 56,115,000 | 59,937,000 | 72,152,000 | 76,433,000 | 75,125,000 | 78,633,000 | 70,313,000 | 72,339,000 | 58,052,000 | 61,241,000 | 57,260,000 | 58,151,000 | 55,993,000 | 62,614,000 | 58,352,000 | 59,345,000 | 62,543,000 | 64,151,000 | 50,037,000 | 36,105,000 | 32,709,000 | 16,781,000 | 13,919,000 | 13,105,000 | 19,194,000 | 17,469,000 | 16,772,000 | 15,321,000 | 14,329,000 | 13,059,000 | 10,436,000 | 10,391,000 | 11,839,000 | 12,028,000 | 11,219,000 | 10,799,000 | 9,411,000 | 11,534,000 | 10,270,000 | 11,842,000 | 11,879,000 | 15,432,000 | 11,802,000 | 14,147,000 | 18,010,000 | 17,107,000 | 15,448,000 | 12,520,000 |
deferred tax liabilities | 636,000 | 1,214,000 | 1,301,000 | 1,242,000 | 1,470,000 | 1,483,000 | 1,340,000 | 3,644,000 | 4,707,000 | 4,594,000 | 4,342,000 | 4,605,000 | 4,983,000 | |||||||||||||||||||||||||||||||||||
acquisition-related contingent consideration, net of current portion | 257,000 | 257,000 | 583,000 | 573,000 | 570,000 | 561,000 | 14,225,000 | 13,889,000 | 13,446,000 | 518,000 | 484,000 | 4,855,000 | 4,773,000 | 2,498,000 | 2,411,000 | 2,358,000 | 5,732,000 | 5,722,000 | 5,251,000 | 4,467,000 | 1,800,000 | |||||||||||||||||||||||||||
operating lease liabilities, net of current portion | 34,986,000 | 35,603,000 | 36,171,000 | 44,232,000 | 43,092,000 | 43,237,000 | 12,400,000 | 13,553,000 | 8,058,000 | 7,525,000 | 8,720,000 | 9,891,000 | 9,709,000 | 10,648,000 | 11,527,000 | 12,529,000 | 13,485,000 | 14,096,000 | ||||||||||||||||||||||||||||||
total liabilities | 91,994,000 | 96,443,000 | 110,120,000 | 123,047,000 | 120,475,000 | 124,069,000 | 98,979,000 | 101,804,000 | 81,424,000 | 70,804,000 | 70,884,000 | 78,396,000 | 75,860,000 | 81,222,000 | 77,780,000 | 80,047,000 | 88,399,000 | 91,311,000 | 79,276,000 | 56,258,000 | 50,905,000 | 35,931,000 | 31,426,000 | 30,590,000 | 36,678,000 | 35,757,000 | 29,283,000 | 28,137,000 | 39,765,000 | 40,883,000 | 39,660,000 | 39,655,000 | 41,182,000 | 41,444,000 | 40,843,000 | 40,503,000 | 39,256,000 | 41,453,000 | 39,645,000 | 41,079,000 | 40,961,000 | 23,042,000 | 17,415,000 | 19,981,000 | 23,531,000 | 22,725,000 | 22,164,000 | 21,124,000 |
commitments and contingencies | ||||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock, 0.001 par value... | ||||||||||||||||||||||||||||||||||||||||||||||||
common stock, 0.001 par value... | 80,000 | 79,000 | 79,000 | 79,000 | 78,000 | 78,000 | 77,000 | 77,000 | 76,000 | 73,000 | 73,000 | 73,000 | 72,000 | 72,000 | 72,000 | 72,000 | 71,000 | 71,000 | 71,000 | 67,000 | 67,000 | 58,000 | 58,000 | 50,000 | 50,000 | 50,000 | 49,000 | 48,000 | 42,000 | 41,000 | 41,000 | 34,000 | 34,000 | 34,000 | 34,000 | 34,000 | 34,000 | 34,000 | 28,000 | 28,000 | 28,000 | 27,000 | 27,000 | 23,000 | 22,000 | 21,000 | 21,000 | 1,000 |
additional paid-in capital | 1,701,470,000 | 1,695,339,000 | 1,684,587,000 | 1,670,853,000 | 1,660,435,000 | 1,655,961,000 | 1,646,343,000 | 1,627,307,000 | 1,617,465,000 | 1,536,168,000 | 1,528,011,000 | 1,520,638,000 | 1,509,861,000 | 1,500,191,000 | 1,492,044,000 | 1,483,279,000 | 1,477,418,000 | 1,468,683,000 | 1,461,778,000 | 1,303,610,000 | 1,297,626,000 | 702,768,000 | 696,217,000 | 495,523,000 | 488,773,000 | 486,090,000 | 470,202,000 | 462,689,000 | 319,733,000 | 313,800,000 | 310,357,000 | 252,284,000 | 250,238,000 | 248,278,000 | 245,430,000 | 243,409,000 | 241,617,000 | 239,631,000 | 205,658,000 | 203,769,000 | 202,079,000 | 198,497,000 | 196,829,000 | 157,688,000 | 155,141,000 | 143,982,000 | 142,592,000 | 3,181,000 |
accumulated deficit | -348,923,000 | -377,630,000 | -418,779,000 | -437,916,000 | -436,936,000 | -443,983,000 | -449,096,000 | -464,251,000 | -469,985,000 | -468,121,000 | -439,828,000 | -410,210,000 | -401,808,000 | -393,717,000 | -389,873,000 | -381,150,000 | -371,618,000 | -357,157,000 | -346,629,000 | -332,500,000 | -323,462,000 | -281,594,000 | -273,550,000 | -269,426,000 | -258,401,000 | -246,685,000 | -239,227,000 | -238,497,000 | -236,003,000 | -234,086,000 | -230,981,000 | -226,512,000 | -220,264,000 | -211,087,000 | -202,648,000 | -195,599,000 | -188,301,000 | -180,084,000 | -175,681,000 | -170,044,000 | ||||||||
accumulated other comprehensive loss | -8,221,000 | -8,212,000 | -8,220,000 | -11,959,000 | -28,641,000 | -36,090,000 | -21,282,000 | -30,610,000 | -28,907,000 | -24,018,000 | -34,197,000 | -27,783,000 | -26,866,000 | -31,346,000 | -54,066,000 | -38,050,000 | -20,681,000 | -15,083,000 | -8,140,000 | |||||||||||||||||||||||||||||
total stockholders’ equity | 1,344,406,000 | 1,257,667,000 | 1,221,057,000 | 1,194,936,000 | 1,176,042,000 | 1,132,523,000 | 1,118,649,000 | 1,054,059,000 | 1,082,718,000 | 1,081,259,000 | 1,048,177,000 | 1,064,151,000 | 1,085,190,000 | 1,107,080,000 | 971,177,000 | 974,231,000 | 422,725,000 | 226,147,000 | 230,422,000 | 231,024,000 | 224,240,000 | 83,772,000 | 79,417,000 | 25,806,000 | 30,008,000 | 42,816,000 | 47,844,000 | 53,350,000 | 30,005,000 | 33,753,000 | 43,306,000 | 57,811,000 | 65,088,000 | 35,079,000 | 48,283,000 | 45,025,000 | 50,290,000 | |||||||||||
total liabilities and stockholders’ equity | 1,436,400,000 | 1,367,787,000 | 1,344,104,000 | 1,315,411,000 | 1,275,021,000 | 1,234,327,000 | 1,200,073,000 | 1,124,943,000 | 1,161,114,000 | 1,157,119,000 | 1,125,957,000 | 1,144,198,000 | 1,173,589,000 | 1,186,356,000 | 1,027,435,000 | 1,025,136,000 | 454,151,000 | 256,737,000 | 267,100,000 | 260,307,000 | 252,377,000 | 123,537,000 | 119,077,000 | 65,461,000 | 71,190,000 | 83,659,000 | 88,347,000 | 92,606,000 | 69,650,000 | 74,832,000 | 84,267,000 | 80,853,000 | 82,503,000 | 55,060,000 | 71,814,000 | 67,750,000 | 72,454,000 | |||||||||||
supplies and inventory | 20,546,000 | 20,327,000 | 25,020,000 | 24,254,000 | 21,750,000 | 20,364,000 | 19,258,000 | 18,328,000 | 16,128,000 | 15,887,000 | 11,572,000 | 13,306,000 | 14,294,000 | 13,798,000 | 14,600,000 | 12,372,000 | ||||||||||||||||||||||||||||||||
liabilities and stockholders' equity | ||||||||||||||||||||||||||||||||||||||||||||||||
current portion of other liabilities | 7,000 | 19,000 | 53,000 | 72,000 | 89,000 | 101,000 | 106,000 | 119,000 | 127,000 | 186,000 | 180,000 | 198,000 | 218,000 | 231,000 | 241,000 | |||||||||||||||||||||||||||||||||
deferred tax liability | 646,000 | 1,227,000 | 734,000 | 4,531,000 | 5,592,000 | 6,234,000 | 773,000 | 750,000 | 222,000 | 254,000 | 300,000 | 325,000 | ||||||||||||||||||||||||||||||||||||
other liabilities | 508,000 | 446,000 | 411,000 | 571,000 | 540,000 | 528,000 | 786,000 | 776,000 | 792,000 | 791,000 | 931,000 | 1,148,000 | 1,210,000 | 1,378,000 | 1,407,000 | 1,891,000 | ||||||||||||||||||||||||||||||||
stockholders' equity: | ||||||||||||||||||||||||||||||||||||||||||||||||
total stockholders' equity | 1,309,576,000 | 1,175,966,000 | 1,044,102,000 | 1,075,200,000 | 1,096,514,000 | 421,232,000 | 239,455,000 | 79,755,000 | 37,225,000 | 59,581,000 | ||||||||||||||||||||||||||||||||||||||
total liabilities and stockholders' equity | 1,406,019,000 | 1,300,035,000 | 1,114,906,000 | 1,156,422,000 | 1,187,825,000 | 457,163,000 | 275,212,000 | 120,638,000 | 78,669,000 | 101,034,000 | ||||||||||||||||||||||||||||||||||||||
property and equipment | 17,702,000 | 17,237,000 | 17,188,000 | 16,299,000 | 15,098,000 | 14,868,000 | 11,813,000 | 10,562,000 | 8,990,000 | 8,914,000 | 8,640,000 | 8,788,000 | 8,933,000 | 8,488,000 | 8,150,000 | 8,114,000 | 8,940,000 | 8,939,000 | 9,035,000 | 9,215,000 | 9,688,000 | 10,281,000 | 10,093,000 | 10,657,000 | 11,480,000 | 10,435,000 | 10,937,000 | 11,272,000 | 6,200,000 | 4,211,000 | 4,132,000 | 3,792,000 | 3,312,000 | 3,028,000 | 2,826,000 | |||||||||||||
right-of-use assets - operating leases | 13,160,000 | 16,043,000 | ||||||||||||||||||||||||||||||||||||||||||||||
current portion of long-term debt | 1,187,000 | 1,133,000 | 1,079,000 | 1,127,000 | 1,357,000 | 1,420,000 | 940,000 | 467,000 | ||||||||||||||||||||||||||||||||||||||||
deferred revenue, net of current portion | 278,000 | 343,000 | 552,000 | 662,000 | 747,000 | 829,000 | ||||||||||||||||||||||||||||||||||||||||||
long-term debt | 1,075,000 | 917,000 | 863,000 | 810,000 | 756,000 | 801,000 | 748,000 | 694,000 | 639,000 | 585,000 | 12,854,000 | 23,925,000 | 25,192,000 | 25,103,000 | 25,016,000 | 24,938,000 | 24,997,000 | 24,971,000 | 24,944,000 | 24,918,000 | 24,891,000 | 24,671,000 | 24,452,000 | 5,002,000 | 4,975,000 | 4,949,000 | 3,587,000 | 4,031,000 | 4,467,000 | 4,863,000 | ||||||||||||||||||
right-of-use assets, operating lease | 16,001,000 | 14,559,000 | ||||||||||||||||||||||||||||||||||||||||||||||
current portion of operating lease liability | 3,465,000 | 2,936,000 | 2,878,000 | 1,589,000 | 1,542,000 | 1,495,000 | 1,450,000 | 1,407,000 | 1,365,000 | 1,284,000 | 1,244,000 | |||||||||||||||||||||||||||||||||||||
operating lease liability, net of current portion | 14,236,000 | 13,334,000 | 14,036,000 | 9,917,000 | 10,331,000 | 10,736,000 | 11,132,000 | 11,506,000 | 11,872,000 | 12,231,000 | 12,582,000 | |||||||||||||||||||||||||||||||||||||
right-of-use assets - operating lease | 15,186,000 | 7,843,000 | 8,094,000 | 8,339,000 | 8,576,000 | 8,808,000 | 9,033,000 | 9,412,000 | 9,630,000 | |||||||||||||||||||||||||||||||||||||||
current portion of acquisition related contingent consideration | 5,986,000 | |||||||||||||||||||||||||||||||||||||||||||||||
finite-lived intangible assets | 59,924,000 | 61,197,000 | 62,471,000 | 63,744,000 | 65,019,000 | 11,200,000 | 11,467,000 | 11,733,000 | 12,000,000 | 12,267,000 | 12,533,000 | 12,800,000 | 13,067,000 | 13,333,000 | 13,600,000 | 13,867,000 | 14,133,000 | 14,400,000 | 14,666,000 | 14,933,000 | 15,467,000 | 15,733,000 | ||||||||||||||||||||||||||
acquisition related contingent consideration | 7,594,000 | 6,088,000 | ||||||||||||||||||||||||||||||||||||||||||||||
acquisition-related contingent consideration | 6,420,000 | 5,948,000 | 5,604,000 | |||||||||||||||||||||||||||||||||||||||||||||
deferred rent, net of current portion | 3,899,000 | 3,953,000 | 4,005,000 | 4,094,000 | 4,170,000 | 4,245,000 | 4,277,000 | 4,373,000 | 4,402,000 | 4,484,000 | 4,566,000 | 4,630,000 | 2,386,000 | 384,000 | 111,000 | 186,000 | 223,000 | 260,000 | 250,000 | |||||||||||||||||||||||||||||
right-of-use assets - finance lease | 619,000 | 677,000 | 735,000 | |||||||||||||||||||||||||||||||||||||||||||||
current portion of finance lease liability | 79,000 | 156,000 | 233,000 | |||||||||||||||||||||||||||||||||||||||||||||
capital lease liability, net of current portion | 79,000 | 156,000 | 233,000 | 308,000 | 382,000 | 456,000 | 528,000 | 599,000 | ||||||||||||||||||||||||||||||||||||||||
supplies inventory | 3,049,000 | 4,557,000 | 5,324,000 | 3,760,000 | 3,317,000 | 3,443,000 | 3,475,000 | 3,416,000 | 3,502,000 | 3,652,000 | 3,984,000 | 3,976,000 | 3,732,000 | 3,350,000 | 3,300,000 | 2,721,000 | 1,392,000 | |||||||||||||||||||||||||||||||
deferred genzyme co-promotion fee | 227,000 | 518,000 | 1,423,000 | 1,897,000 | 1,897,000 | 1,897,000 | 2,500,000 | 2,500,000 | 2,500,000 | |||||||||||||||||||||||||||||||||||||||
deferred tax asset | 222,000 | 254,000 | 300,000 | 325,000 | ||||||||||||||||||||||||||||||||||||||||||||
indefinite-lived intangible assets: in-process research and development | ||||||||||||||||||||||||||||||||||||||||||||||||
deferred genzyme co-promotion fee, net of current portion | 474,000 | 1,423,000 | 1,364,000 | 1,989,000 | 3,239,000 | |||||||||||||||||||||||||||||||||||||||||||
in-process research and development | 16,000,000 | 16,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ (deficit) equity | ||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock liability | ||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock warrant liability | 252,000 | |||||||||||||||||||||||||||||||||||||||||||||||
convertible preferred stock; 0.001 par value... | 79,022,000 | |||||||||||||||||||||||||||||||||||||||||||||||
stockholders’ (deficit) equity: | ||||||||||||||||||||||||||||||||||||||||||||||||
total stockholders’ (deficit) equity | ||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities, convertible preferred stock, and stockholders’ (deficit) equity | 23,571,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
operating activities | |||||||||||||||||||||||||||||||||||||||||||||||
net income | 28,707,000 | 41,149,000 | 19,137,000 | -980,000 | 7,047,000 | 5,113,000 | 15,155,000 | ||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 5,430,000 | 5,298,000 | 5,266,000 | 5,489,000 | 5,362,000 | 6,253,000 | 5,878,000 | 5,738,000 | 5,590,000 | 6,336,000 | 7,323,000 | 6,859,000 | 6,670,000 | 6,556,000 | 6,324,000 | 6,492,000 | 6,556,000 | 6,404,000 | 6,139,000 | 4,500,000 | 2,550,000 | 2,025,000 | 1,990,000 | 1,957,000 | 1,972,000 | 1,281,000 | 967,000 | 924,000 | 945,000 | 970,000 | 981,000 | 989,000 | 980,000 | 1,002,000 | 993,000 | 944,000 | 902,000 | 909,000 | 899,000 | 941,000 | 762,000 | 646,000 | 644,000 | 352,000 | 292,000 | 277,000 | 264,000 |
loss on disposal of property, plant and equipment | 366,000 | 0 | 0 | 71,000 | 63,000 | 38,000 | 30,000 | 0 | 15,000 | 121,000 | |||||||||||||||||||||||||||||||||||||
stock-based compensation | 12,761,000 | 10,901,000 | 10,757,000 | 10,985,000 | 10,958,000 | 9,629,000 | 8,747,000 | 9,854,000 | 8,019,000 | 7,512,000 | 7,263,000 | 10,381,000 | 7,985,000 | 6,867,000 | 7,283,000 | 5,939,000 | 6,645,000 | 6,732,000 | 7,868,000 | 4,064,000 | 3,855,000 | 3,641,000 | 3,089,000 | 3,360,000 | 2,905,000 | 2,842,000 | 2,640,000 | 2,566,000 | 1,759,000 | 1,533,000 | 1,519,000 | 1,731,000 | 1,175,000 | 1,792,000 | 1,611,000 | 1,642,000 | 1,572,000 | 1,633,000 | 1,572,000 | 1,677,000 | 1,496,000 | 1,474,000 | 1,489,000 | 1,223,000 | 1,035,000 | 875,000 | 492,000 |
deferred income taxes | -10,000 | -568,000 | -87,000 | 59,000 | 15,000 | -243,000 | -13,000 | 143,000 | -120,000 | -2,996,000 | -968,000 | ||||||||||||||||||||||||||||||||||||
noncash lease expense | 732,000 | 689,000 | 696,000 | 904,000 | 1,327,000 | 1,341,000 | 1,148,000 | 1,139,000 | 1,028,000 | 1,153,000 | 1,074,000 | 903,000 | 833,000 | 849,000 | 1,051,000 | 587,000 | 66,000 | 681,000 | 627,000 | 258,000 | 250,000 | 245,000 | 237,000 | 232,000 | |||||||||||||||||||||||
revaluation of acquisition-related contingent consideration | -350,000 | -12,582,000 | 166,000 | -925,000 | -1,954,000 | 925,000 | 379,000 | 858,000 | 5,000 | 117,000 | -5,156,000 | 141,000 | -485,000 | 234,000 | -32,000 | -79,000 | 31,000 | 507,000 | 56,000 | 55,000 | 192,000 | 1,174,000 | 472,000 | 344,000 | -484,000 | ||||||||||||||||||||||
effect of foreign currency on operations | -80,000 | 11,000 | 1,205,000 | -3,465,000 | -1,585,000 | 2,895,000 | -1,681,000 | 259,000 | 637,000 | -1,753,000 | 824,000 | 57,000 | -224,000 | -1,041,000 | 847,000 | 585,000 | 131,000 | -390,000 | -265,000 | 1,784,000 | 82,000 | -17,000 | |||||||||||||||||||||||||
amortization of discount on short-term investments | -614,000 | -651,000 | |||||||||||||||||||||||||||||||||||||||||||||
changes in operating assets and liabilities: | |||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -5,567,000 | 3,150,000 | 425,000 | 2,770,000 | -7,053,000 | 1,991,000 | 1,690,000 | -3,627,000 | -6,459,000 | -763,000 | 2,861,000 | 3,091,000 | -1,302,000 | -139,000 | -1,420,000 | 639,000 | -3,575,000 | -2,286,000 | 428,000 | -2,965,000 | -3,748,000 | -787,000 | -2,281,000 | 3,785,000 | 238,000 | 4,284,000 | -3,987,000 | -3,011,000 | -3,447,000 | -906,000 | 744,000 | 192,000 | -482,000 | -1,081,000 | -608,000 | -1,902,000 | -369,000 | -2,444,000 | -2,925,000 | -159,000 | 207,000 | 466,000 | |||||
supplies | -870,000 | -1,468,000 | 379,000 | -365,000 | -10,000 | -201,000 | 2,585,000 | -947,000 | -376,000 | -198,000 | -1,504,000 | -1,336,000 | -366,000 | 61,000 | |||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | -1,306,000 | 4,362,000 | -956,000 | -2,532,000 | -2,928,000 | -1,445,000 | 2,332,000 | 555,000 | -2,738,000 | 1,120,000 | 952,000 | 534,000 | -3,064,000 | 1,415,000 | 1,805,000 | 309,000 | -2,139,000 | -1,411,000 | -617,000 | -1,420,000 | 132,000 | -47,000 | -259,000 | 154,000 | -818,000 | -31,000 | 377,000 | -181,000 | -11,000 | 38,000 | |||||||||||||||||
other assets | -132,000 | 194,000 | 1,720,000 | -629,000 | -760,000 | 134,000 | -497,000 | -1,472,000 | 259,000 | -172,000 | 462,000 | -557,000 | -491,000 | -3,209,000 | -124,000 | -167,000 | 451,000 | -569,000 | 383,000 | 28,000 | -58,000 | -97,000 | -32,000 | 31,000 | 135,000 | -209,000 | -167,000 | -12,000 | 37,000 | -249,000 | -239,000 | -132,000 | -140,000 | -148,000 | 7,000 | 69,000 | -31,000 | ||||||||||
operating lease liabilities | -319,000 | -495,000 | -609,000 | -577,000 | -1,483,000 | -1,393,000 | -1,053,000 | -1,134,000 | -1,141,000 | -950,000 | -890,000 | -1,083,000 | -597,000 | ||||||||||||||||||||||||||||||||||
accounts payable | 2,587,000 | -492,000 | -3,660,000 | -4,007,000 | 7,120,000 | -1,355,000 | -1,244,000 | -162,000 | -1,544,000 | -319,000 | -607,000 | -1,220,000 | 2,012,000 | 477,000 | 1,048,000 | -413,000 | -960,000 | 1,283,000 | 1,114,000 | 827,000 | 1,931,000 | 1,245,000 | -656,000 | -5,328,000 | 5,450,000 | -2,646,000 | 759,000 | 20,000 | 1,726,000 | 1,068,000 | -724,000 | -1,402,000 | -510,000 | 837,000 | 625,000 | -262,000 | 528,000 | -1,054,000 | 418,000 | -1,106,000 | 301,000 | -79,000 | 1,332,000 | 2,045,000 | |||
accrued liabilities and deferred revenue | -6,120,000 | -718,000 | 9,125,000 | 6,798,000 | -8,889,000 | -351,000 | 20,000 | 12,865,000 | -8,993,000 | 2,724,000 | 334,000 | 3,987,000 | -7,721,000 | 2,106,000 | -728,000 | -4,908,000 | -390,000 | 11,096,000 | -1,441,000 | 4,532,000 | 238,000 | ||||||||||||||||||||||||||
net cash from operating activities | 35,215,000 | 52,583,000 | 44,757,000 | 33,605,000 | 5,362,000 | 24,524,000 | 29,963,000 | 29,575,000 | -8,966,000 | 15,552,000 | 14,171,000 | 16,671,000 | -2,172,000 | 9,744,000 | 7,026,000 | -363,000 | -8,872,000 | 8,446,000 | -1,393,000 | 1,887,000 | -40,561,000 | 2,261,000 | 1,752,000 | -8,423,000 | -5,301,000 | 1,790,000 | -1,556,000 | -2,455,000 | -1,011,000 | -1,226,000 | -1,783,000 | -3,099,000 | -7,413,000 | -5,816,000 | -5,103,000 | -4,910,000 | -8,086,000 | -4,232,000 | -7,438,000 | ||||||||
capital expenditures | -645,000 | -3,780,000 | -2,469,000 | -1,758,000 | -842,000 | -4,141,000 | -3,581,000 | -2,633,000 | -380,000 | -2,497,000 | -2,488,000 | -5,183,000 | 631,000 | -1,872,000 | -1,768,000 | -2,783,000 | -2,111,000 | -841,000 | -2,800,000 | -865,000 | -839,000 | -888,000 | -635,000 | -649,000 | -552,000 | -1,100,000 | -232,000 | -659,000 | -670,000 | -204,000 | -659,000 | -534,000 | -171,000 | -446,000 | -727,000 | -113,000 | -450,000 | -173,000 | |||||||||
free cash flows | 34,570,000 | 48,803,000 | 42,288,000 | 31,847,000 | 4,520,000 | 20,383,000 | 26,382,000 | 26,942,000 | -9,346,000 | 13,055,000 | 11,683,000 | 11,488,000 | -1,541,000 | 7,872,000 | 5,258,000 | -3,146,000 | -10,983,000 | 7,605,000 | -4,193,000 | 1,022,000 | -41,400,000 | 1,373,000 | 1,117,000 | -9,072,000 | -5,853,000 | 690,000 | -1,788,000 | -3,114,000 | -1,681,000 | -1,430,000 | -2,442,000 | -3,633,000 | -7,584,000 | -6,262,000 | -5,830,000 | -5,023,000 | -4,682,000 | -7,611,000 | |||||||||
investing activities | |||||||||||||||||||||||||||||||||||||||||||||||
purchase of short-term investments | -124,999,000 | -50,000,000 | 0 | -49,999,000 | -49,999,000 | 0 | 0 | 0 | -19,700,000 | -24,547,000 | 0 | ||||||||||||||||||||||||||||||||||||
purchases of property, plant and equipment | -2,962,000 | -3,780,000 | -2,792,000 | -1,286,000 | -1,819,000 | -4,141,000 | -2,242,000 | -2,770,000 | -2,134,000 | -2,497,000 | -2,802,000 | -3,669,000 | -993,000 | ||||||||||||||||||||||||||||||||||
net cash from investing activities | -127,961,000 | -5,430,000 | 48,263,000 | -224,000 | -51,818,000 | -54,141,000 | -2,242,000 | -2,770,000 | 2,878,000 | -2,497,000 | -2,802,000 | -3,669,000 | 24,080,000 | -26,434,000 | 8,807,000 | -9,307,000 | -2,453,000 | 385,000 | -165,457,000 | 1,473,000 | -575,607,000 | -888,000 | -1,635,000 | -649,000 | -665,000 | -41,100,000 | -226,000 | -658,000 | -749,000 | -454,000 | -659,000 | -534,000 | -227,000 | -300,000 | -607,000 | -113,000 | -175,000 | -450,000 | -173,000 | ||||||||
financing activities | |||||||||||||||||||||||||||||||||||||||||||||||
payment of taxes on vested restricted stock units | -9,364,000 | -3,659,000 | -2,814,000 | -2,380,000 | -9,451,000 | -3,274,000 | -2,180,000 | -1,303,000 | -3,832,000 | -1,127,000 | -2,446,000 | -891,000 | -2,277,000 | -528,000 | -774,000 | -418,000 | -1,447,000 | -722,000 | -823,000 | -710,000 | -6,774,000 | -684,000 | -483,000 | -374,000 | -2,304,000 | ||||||||||||||||||||||
proceeds from the exercise of common stock options and employee stock purchases | 2,735,000 | 3,510,000 | 5,791,000 | 1,814,000 | 2,967,000 | 3,264,000 | 12,469,000 | 1,292,000 | 2,968,000 | 1,772,000 | 2,556,000 | 1,288,000 | 3,962,000 | 1,808,000 | 2,257,000 | 340,000 | 3,537,000 | 895,000 | 4,038,000 | 2,630,000 | 3,965,000 | 3,595,000 | 4,265,000 | 3,764,000 | 2,085,000 | 3,044,000 | 4,874,000 | 2,548,000 | 4,181,000 | 1,905,000 | 1,564,000 | 312,000 | 569,000 | 923,000 | 511,000 | 49,000 | 414,000 | 253,000 | 317,000 | 13,000 | 633,000 | ||||||
net cash from financing activities | -6,629,000 | -149,000 | 2,977,000 | -566,000 | -6,484,000 | -4,510,000 | 10,289,000 | -11,000 | -864,000 | 645,000 | 110,000 | 397,000 | 1,685,000 | 93,000 | 1,486,000 | -75,000 | 1,990,000 | 173,000 | 3,215,000 | 1,920,000 | 591,012,000 | 2,911,000 | 197,513,000 | 3,390,000 | -219,000 | 2,965,000 | 4,797,000 | 127,919,000 | -8,394,000 | 1,829,000 | 56,530,000 | 239,000 | 901,000 | -1,188,000 | 442,000 | -20,000 | 548,000 | 32,202,000 | 317,000 | 92,000 | 109,000 | ||||||
decrease in cash, cash equivalents and restricted cash | -99,375,000 | -52,940,000 | 17,319,000 | -9,745,000 | -9,335,000 | ||||||||||||||||||||||||||||||||||||||||||
effect of foreign currency on cash, cash equivalents and restricted cash | -58,000 | 12,000 | 60,000 | 573,000 | 74,000 | -401,000 | 146,000 | -61,000 | -108,000 | 297,000 | -177,000 | -7,000 | 50,000 | 732,000 | -654,000 | -423,000 | -247,000 | 164,000 | 119,000 | ||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -99,433,000 | -52,866,000 | 16,665,000 | -10,168,000 | -9,582,000 | 3,483,000 | -25,156,000 | -6,185,000 | -10,154,000 | -3,394,000 | -6,739,000 | ||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of period | 364,226,000 | 0 | 0 | 240,631,000 | 0 | 0 | 217,330,000 | 0 | 0 | 154,996,000 | 0 | 0 | 173,946,000 | 0 | 0 | 349,967,000 | 0 | 0 | 159,920,000 | 0 | 0 | 78,598,000 | 0 | 0 | 34,494,000 | ||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 264,793,000 | 96,057,000 | 33,388,000 | 187,765,000 | 38,156,000 | 26,733,000 | 210,270,000 | 11,302,000 | 13,392,000 | 178,639,000 | 16,665,000 | -10,168,000 | 164,364,000 | -163,516,000 | 3,483,000 | 324,811,000 | 197,630,000 | -5,682,000 | 153,735,000 | 3,015,000 | 124,806,000 | 68,444,000 | 54,088,000 | -3,394,000 | 27,755,000 | ||||||||||||||||||||||
supplementary cash flow information: | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of property, plant and equipment included in accounts payable and accrued liability | 2,317,000 | 323,000 | -472,000 | 977,000 | -1,339,000 | 137,000 | 1,754,000 | 314,000 | -1,514,000 | 1,624,000 | |||||||||||||||||||||||||||||||||||||
cash paid for tax | 164,000 | 835,000 | 1,432,000 | 121,000 | 1,031,000 | 1,188,000 | 428,000 | 140,000 | 366,000 | ||||||||||||||||||||||||||||||||||||||
non-cash lease expense | |||||||||||||||||||||||||||||||||||||||||||||||
impairment loss | 0 | 0 | 2,754,000 | 185,000 | 0 | 429,000 | 32,039,000 | 34,900,000 | 0 | 1,410,000 | |||||||||||||||||||||||||||||||||||||
non-cash loss on deconsolidation of subsidiary | 2,845,000 | ||||||||||||||||||||||||||||||||||||||||||||||
supplies and inventory | -219,000 | 221,000 | -565,000 | -2,298,000 | -1,696,000 | -909,000 | -963,000 | -2,303,000 | -58,000 | -4,418,000 | 1,727,000 | 1,055,000 | -170,000 | 813,000 | -2,453,000 | -1,201,000 | |||||||||||||||||||||||||||||||
operating lease liability | -84,000 | -693,000 | -644,000 | -373,000 | -367,000 | -358,000 | -351,000 | -331,000 | |||||||||||||||||||||||||||||||||||||||
proceeds from sale of short-term investments | 0 | 0 | 0 | 39,773,000 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from maturity of short-term investments | 51,195,000 | 51,055,000 | 0 | 0 | 0 | 5,000,000 | -15,000 | 10,521,000 | |||||||||||||||||||||||||||||||||||||||
loss on deconsolidation of subsidiary - cash | |||||||||||||||||||||||||||||||||||||||||||||||
acquisition of c2i, net of cash acquired | 0 | 0 | 0 | 5,012,000 | |||||||||||||||||||||||||||||||||||||||||||
payment of contingent consideration for acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
increase in cash, cash equivalents and restricted cash | 47,004,000 | 95,997,000 | -34,127,000 | 38,010,000 | 26,794,000 | -6,952,000 | 13,700,000 | 11,479,000 | 13,399,000 | 23,593,000 | 9,004,000 | ||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | 47,016,000 | 96,057,000 | -34,528,000 | 38,156,000 | 26,733,000 | -7,060,000 | 13,997,000 | 11,302,000 | 13,392,000 | 23,643,000 | 9,168,000 | 4,284,000 | 197,630,000 | -36,345,000 | 3,015,000 | 149,000 | |||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of year | |||||||||||||||||||||||||||||||||||||||||||||||
supplementary cash flow information of non-cash investing and financing activities: | |||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment included in accounts payable and accrued liabilities | 95,000 | 250,000 | 56,000 | -146,000 | -381,000 | 423,000 | |||||||||||||||||||||||||||||||||||||||||
interest on end-of-term debt obligation | 0 | 54,000 | 54,000 | 53,000 | 55,000 | 54,000 | 54,000 | 53,000 | 54,000 | 55,000 | 53,000 | 54,000 | 54,000 | 56,000 | 64,000 | 81,000 | 79,000 | 70,000 | |||||||||||||||||||||||||||||
payment of long-term debt | -1,187,000 | 3,000 | 3,000 | -100,000 | 0 | 0 | 0 | -12,400,000 | -12,500,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||
cash paid for interest on debt | |||||||||||||||||||||||||||||||||||||||||||||||
net loss | -1,864,000 | -28,293,000 | -29,618,000 | -8,402,000 | -8,091,000 | -3,844,000 | -8,723,000 | -9,532,000 | -14,461,000 | -10,528,000 | -14,129,000 | -9,038,000 | -41,868,000 | -8,044,000 | -4,124,000 | -11,025,000 | -11,716,000 | -7,458,000 | -730,000 | -2,494,000 | -1,917,000 | -3,105,000 | -4,469,000 | -6,248,000 | -9,177,000 | -8,439,000 | -7,049,000 | -7,298,000 | -8,217,000 | -4,403,000 | -5,637,000 | -11,243,000 | -10,075,000 | -8,945,000 | -9,136,000 | -7,610,000 | -7,902,000 | -6,655,000 | -6,674,000 | ||||||||
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
loss on disposal of property and equipment | 134,000 | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||
acquisition of decipher biosciences, net of cash acquired | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
acquisition of haliodx, net of cash acquired | 1,226,000 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of equity securities | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock in a public offering, net of issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
shares issued for purchase consideration for a business combination | |||||||||||||||||||||||||||||||||||||||||||||||
benefit from income taxes | -152,000 | -115,000 | -3,000 | -961,000 | -1,350,000 | -152,000 | -3,795,000 | ||||||||||||||||||||||||||||||||||||||||
provision for income taxes | |||||||||||||||||||||||||||||||||||||||||||||||
write-down of excess supplies | 0 | 0 | 0 | 1,088,000 | |||||||||||||||||||||||||||||||||||||||||||
purchase of equity securities | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment | -1,872,000 | -1,714,000 | -2,510,000 | -2,453,000 | -841,000 | -1,812,000 | -1,527,000 | -1,196,000 | -888,000 | -635,000 | -649,000 | -665,000 | -1,100,000 | -232,000 | -659,000 | -765,000 | -454,000 | -659,000 | -534,000 | -227,000 | -300,000 | -727,000 | -113,000 | -615,000 | -450,000 | -173,000 | |||||||||||||||||||||
impairment of intangible assets | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock in a public offering, net of issuance costs | 0 | 0 | 593,821,000 | ||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment included in accounts payable and accrued liability | -54,000 | -273,000 | 342,000 | -988,000 | 662,000 | 357,000 | 113,000 | ||||||||||||||||||||||||||||||||||||||||
interest paid on debt | 0 | 0 | 2,000 | 1,000 | 11,000 | 91,000 | 228,000 | 494,000 | 385,000 | 356,000 | |||||||||||||||||||||||||||||||||||||
issuance of common stock for acquisition of haliodx | |||||||||||||||||||||||||||||||||||||||||||||||
gain on disposal of property and equipment | -6,000 | -1,000 | -16,000 | ||||||||||||||||||||||||||||||||||||||||||||
amortization and write-off of debt discount and issuance costs | 393,000 | 26,000 | 27,000 | 26,000 | 27,000 | 27,000 | 92,000 | ||||||||||||||||||||||||||||||||||||||||
acquisition of nanostring diagnostics platform | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the sale of property and equipment | |||||||||||||||||||||||||||||||||||||||||||||||
payment of financial lease liability | |||||||||||||||||||||||||||||||||||||||||||||||
deferred purchase consideration for a business combination | |||||||||||||||||||||||||||||||||||||||||||||||
acquisition of business, net of cash acquired | 0 | -574,411,000 | |||||||||||||||||||||||||||||||||||||||||||||
other income | 0 | 0 | 0 | -93,000 | |||||||||||||||||||||||||||||||||||||||||||
accrued liabilities, deferred revenue and deferred rent | |||||||||||||||||||||||||||||||||||||||||||||||
cash paid for acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from legal settlement regarding short-swing profits | 0 | 0 | 0 | 403,000 | |||||||||||||||||||||||||||||||||||||||||||
amortization of debt issuance costs | 0 | 75,000 | 8,000 | 8,000 | 8,000 | 8,000 | |||||||||||||||||||||||||||||||||||||||||
accrued liabilities | 1,043,000 | -693,000 | -3,650,000 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from disposal of property and equipment | 6,000 | 1,000 | 16,000 | ||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock in a public offering | |||||||||||||||||||||||||||||||||||||||||||||||
payment of finance lease liability | -77,000 | -77,000 | -75,000 | ||||||||||||||||||||||||||||||||||||||||||||
interest on end-of-term debt obligation and prepayment penalty | |||||||||||||||||||||||||||||||||||||||||||||||
right-of-use assets - operating lease and operating lease liability | -100,000 | 102,000 | -93,000 | -80,000 | |||||||||||||||||||||||||||||||||||||||||||
accrued liabilities and deferred rent | 3,970,000 | -61,000 | 1,032,000 | 287,000 | -110,000 | 767,000 | -161,000 | 228,000 | 38,000 | -429,000 | 1,551,000 | -2,323,000 | 1,542,000 | -1,803,000 | |||||||||||||||||||||||||||||||||
proceeds from the issuance of long-term debt, net of debt issuance costs | 0 | 0 | -148,000 | 24,600,000 | |||||||||||||||||||||||||||||||||||||||||||
payment of end-of-term debt obligation and prepayment penalty | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||
operating lease liability arising from obtaining right-of-use assets - operating lease at beginning of period | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock in a public offering, net of costs | 0 | 0 | 0 | 200,000 | |||||||||||||||||||||||||||||||||||||||||||
operating lease liability arising from obtaining right-of-use assets - operating lease | 0 | 14,118,000 | |||||||||||||||||||||||||||||||||||||||||||||
purchases of property and equipment included in accounts payable | |||||||||||||||||||||||||||||||||||||||||||||||
bad debt expense | 0 | 0 | 2,000 | 66,000 | 26,000 | 32,000 | 22,000 | 28,000 | 11,000 | 28,000 | |||||||||||||||||||||||||||||||||||||
genzyme co-promotion fee amortization | 0 | -227,000 | |||||||||||||||||||||||||||||||||||||||||||||
conversion of accrued interest to long-term debt | 0 | 193,000 | |||||||||||||||||||||||||||||||||||||||||||||
payment of capital lease liability | -75,000 | -73,000 | -73,000 | -71,000 | -70,000 | -69,000 | -69,000 | -66,000 | |||||||||||||||||||||||||||||||||||||||
net receivable for reimbursement of public offering issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and current other assets | -37,000 | 337,000 | -239,000 | -247,000 | 215,000 | 269,000 | -244,000 | -452,000 | -10,000 | -370,000 | 463,000 | ||||||||||||||||||||||||||||||||||||
proceeds from sale of property and equipment | 0 | 0 | 440,000 | ||||||||||||||||||||||||||||||||||||||||||||
supplies inventory | 1,508,000 | 767,000 | -1,564,000 | -443,000 | 126,000 | 32,000 | -59,000 | 86,000 | 150,000 | 115,000 | |||||||||||||||||||||||||||||||||||||
change in restricted cash | 0 | 0 | 0 | 70,000 | |||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock in a private placement, net of issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
payment of deferred stock offering costs | |||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -7,713,000 | 27,520,000 | -7,294,000 | -8,463,000 | 8,372,000 | ||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of year | |||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of year | |||||||||||||||||||||||||||||||||||||||||||||||
conversion of accrued interest on long-term debt | |||||||||||||||||||||||||||||||||||||||||||||||
interest on debt balloon payment and prepayment penalty | 0 | 0 | 0 | 206,000 | |||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | -5,268,000 | ||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of period | 0 | 0 | 59,219,000 | 0 | 0 | 0 | 39,084,000 | 0 | 0 | 35,014,000 | 0 | 0 | 71,220,000 | ||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | -5,268,000 | -5,043,000 | 51,506,000 | 27,520,000 | -7,294,000 | -8,463,000 | 47,456,000 | -4,929,000 | 25,247,000 | 25,798,000 | -13,996,000 | -6,239,000 | 64,237,000 | ||||||||||||||||||||||||||||||||||
unpaid deferred stock offering | |||||||||||||||||||||||||||||||||||||||||||||||
amortization of debt discount and issuance costs | 11,000 | 12,000 | 11,000 | 27,000 | 28,000 | 26,000 | |||||||||||||||||||||||||||||||||||||||||
cash remitted for acquisition, net of cash received | |||||||||||||||||||||||||||||||||||||||||||||||
commissions and issuance costs relating to initial public offering | |||||||||||||||||||||||||||||||||||||||||||||||
fair value of common stock issued for acquisition | |||||||||||||||||||||||||||||||||||||||||||||||
non-cash issuance of long-term debt | |||||||||||||||||||||||||||||||||||||||||||||||
non-cash repayment of long-term debt | |||||||||||||||||||||||||||||||||||||||||||||||
issuance of common stock from the non-cash exercise of common stock warrants | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of common stock in a private placement, net of costs | |||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by financing activities | 19,945,000 | ||||||||||||||||||||||||||||||||||||||||||||||
unpaid deferred debt issuance costs | 148,000 | ||||||||||||||||||||||||||||||||||||||||||||||
interest on debt balloon payment | 20,000 | 20,000 | 19,000 | 20,000 | 20,000 | 20,000 | |||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of common stock in a private placement, net of costs | 0 | ||||||||||||||||||||||||||||||||||||||||||||||
commissions and issuance costs relating to the initial public offering | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the exercise of common stock options | 193,000 | 399,000 | 92,000 | 109,000 | 448,000 | 27,000 | |||||||||||||||||||||||||||||||||||||||||
net increase (decrease) in cash and cash equivalents | |||||||||||||||||||||||||||||||||||||||||||||||
unpaid deferred stock offering costs | |||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||||||||||||||||||||||||||||||||||
change in value of preferred stock liability | |||||||||||||||||||||||||||||||||||||||||||||||
change in value of preferred stock warrant liability | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of long-term debt, net of debt issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of redeemable convertible preferred stock, net of issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
payment of convertible preferred stock issuance costs | |||||||||||||||||||||||||||||||||||||||||||||||
equity-based compensation | |||||||||||||||||||||||||||||||||||||||||||||||
accounts receivables | |||||||||||||||||||||||||||||||||||||||||||||||
deferred genzyme co-promotion fee |